Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Cancer Immunology Miniatures

  • Cancer Immunology Miniatures
    Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma
    Leila Khoja, Catherine Maurice, MaryAnne Chappell, Leslie MacMillan, Ayman S. Al-Habeeb, Nada Al-Faraidy, Marcus O. Butler, Patrik Rogalla, Warren Mason, Anthony M. Joshua and David Hogg
    Cancer Immunol Res March 1 2016 4 (3) 175-178; DOI:10.1158/2326-6066.CIR-15-0186

    The patterns and kinetics of toxicity with anti–PD-1 agents are emerging. The incidence of grade 3 or above toxicities is low. We identify an idiosyncratic toxicity, eosinophilic fasciitis, that requires particular clinical vigilance to enable diagnosis and management.

  • Cancer Immunology Miniatures
    Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment
    Justine V. Cohen, Ahmed K. Alomari, Alexander O. Vortmeyer, Lucia B. Jilaveanu, Sarah B. Goldberg, Amit Mahajan, Veronica L. Chiang and Harriet M. Kluger
    Cancer Immunol Res March 1 2016 4 (3) 179-182; DOI:10.1158/2326-6066.CIR-15-0160

    This case report documents pseudoprogression in brain metastases treated with antibodies to PD-1. Use of immune checkpoint inhibitors in melanoma and other malignancies is increasing, making it important to recognize and treat effects unique to brain metastases.

Research Articles

  • Research Articles
    Regulatory T Cells from Colon Cancer Patients Inhibit Effector T-cell Migration through an Adenosine-Dependent Mechanism
    Patrik Sundström, Hanna Stenstad, Veronica Langenes, Filip Ahlmanner, Lisa Theander, Tapuka Gordon Ndah, Kamilla Fredin, Lars Börjesson, Bengt Gustavsson, Jérémy Bastid and Marianne Quiding-Järbrink
    Cancer Immunol Res March 1 2016 4 (3) 183-193; DOI:10.1158/2326-6066.CIR-15-0050

    Regulatory T cells suppress many effector T-cell functions. Tregs from patients with colon cancer were found to inhibit transendothelial migration of conventional T cells, perhaps explaining the paucity of effector T cells within tumors.

  • Research Articles | Free Article
    PD-1 Blockade Expands Intratumoral Memory T Cells
    Antoni Ribas, Daniel Sanghoon Shin, Jesse Zaretsky, Juliet Frederiksen, Andrew Cornish, Earl Avramis, Elizabeth Seja, Christine Kivork, Janet Siebert, Paula Kaplan-Lefko, Xiaoyan Wang, Bartosz Chmielowski, John A. Glaspy, Paul C. Tumeh, Thinle Chodon, Dana Pe'er and Begoña Comin-Anduix
    Cancer Immunol Res March 1 2016 4 (3) 194-203; DOI:10.1158/2326-6066.CIR-15-0210

    Tumor biopsies from patients treated with antibodies to PD-1 showed that therapy altered tumor composition. T cells, B cells, and myeloid-derived suppressor cells were increased, and patients who responded to anti–PD-1 therapy had increased memory CD8+ T cells.

  • Research Articles
    Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors
    Qiong J. Wang, Zhiya Yu, Kayla Griffith, Ken-ichi Hanada, Nicholas P. Restifo and James C. Yang
    Cancer Immunol Res March 1 2016 4 (3) 204-214; DOI:10.1158/2326-6066.CIR-15-0188

    This study identifies HLA-A11*01–restricted T-cell receptors (TCRs) that specifically target mutated KRAS, which is an oncogenic driver mutation found in many types of cancers. These TCRs have antitumor activity and thus show potential for clinical use in multiple cancers.

  • Research Articles | AuthorChoice
    Phase I Study of Random Healthy Donor–Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors
    Yaewon Yang, Okjae Lim, Tae Min Kim, Yong-Oon Ahn, Hana Choi, Hyejin Chung, Bokyung Min, Jung Hyun Her, Sung Yoo Cho, Bhumsuk Keam, Se-Hoon Lee, Dong-Wan Kim, Yu Kyeong Hwang and Dae Seog Heo
    Cancer Immunol Res March 1 2016 4 (3) 215-224; DOI:10.1158/2326-6066.CIR-15-0118

    Completely allogeneic NK cells could provide a ready source of antitumor activity. This preliminary clinical trial shows that such cells are well tolerated and have potential benefits for cancer patients by upregulating the host immune responses against cancer.

  • Research Articles | AuthorChoice
    Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer
    Darshil T. Jhaveri, Min-Sik Kim, Elizabeth D. Thompson, Lanqing Huang, Rajni Sharma, Alison P. Klein, Lei Zheng, Dung T. Le, Daniel A. Laheru, Akhilesh Pandey, Elizabeth M. Jaffee and Robert A. Anders
    Cancer Immunol Res March 1 2016 4 (3) 225-233; DOI:10.1158/2326-6066.CIR-15-0200-T

    Serum samples from patients in a phase II pancreas cancer vaccine clinical trial were subjected to quantitative proteomics. Three highly induced proteins in the pancreas after vaccination became targets of antibodies. Patients harboring these antibodies had improved clinical outcomes.

  • Research Articles
    Comprehensive Immune Profiling of Lung Adenocarcinomas Reveals Four Immunosubtypes with Plasma Cell Subtype a Negative Indicator
    Yutaka Kurebayashi, Katsura Emoto, Yuichiro Hayashi, Ikuo Kamiyama, Takashi Ohtsuka, Hisao Asamura and Michiie Sakamoto
    Cancer Immunol Res March 1 2016 4 (3) 234-247; DOI:10.1158/2326-6066.CIR-15-0214

    Lung cancer is a complex disease with variable outcomes. Immune cells from 114 cases were quantified immunohistochemically, identifying four immunosubtypes of lung adenocarcinoma (CD8, mast cell, macrophage/DC, and plasma cell) that could potentially be useful for therapy selection.

  • Research Articles
    Immunotherapy against Metastatic Melanoma with Human iPS Cell–Derived Myeloid Cell Lines Producing Type I Interferons
    Azusa Miyashita, Satoshi Fukushima, Satoshi Nakahara, Yosuke Kubo, Aki Tokuzumi, Junji Yamashita, Jun Aoi, Miwa Haruta, Satoru Senju, Yasuharu Nishimura, Masatoshi Jinnin and Hironobu Ihn
    Cancer Immunol Res March 1 2016 4 (3) 248-258; DOI:10.1158/2326-6066.CIR-15-0096

    Human myeloid cell lines derived from iPS cells were genetically modified to express type I IFNs. These cells durably inhibited the growth of human melanoma in xenograft models by infiltrating tumors and providing local antitumor effects.

  • Research Articles
    CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains
    Satoshi Shiina, Masasuke Ohno, Fumiharu Ohka, Shunichiro Kuramitsu, Akane Yamamichi, Akira Kato, Kazuya Motomura, Kuniaki Tanahashi, Takashi Yamamoto, Reiko Watanabe, Ichiro Ito, Takeshi Senga, Michinari Hamaguchi, Toshihiko Wakabayashi, Mika K. Kaneko, Yukinari Kato, Vidyalakshmi Chandramohan, Darell D. Bigner and Atsushi Natsume
    Cancer Immunol Res March 1 2016 4 (3) 259-268; DOI:10.1158/2326-6066.CIR-15-0060

    The glioblastoma subtypes with the worst prognoses often bear podoplanin. T cells expressing a chimeric antigen receptor that targets podoplanin were specific and effective against PDPN-positive glioblastoma cells in vitro and increased survival time in a mouse model.

Back to top
PreviousNext
Cancer Immunology Research: 4 (3)
March 2016
Volume 4, Issue 3
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

Jump to

  • Cancer Immunology Miniatures
  • Research Articles
Advertisement
  • Most Cited
  • Most Read
Loading
  • Activity of Anti-CTLA-4 Isotypes in Antitumor Responses
  • Masters of Immunology
  • Characterization of Murine Syngeneic Tumor Models
  • Extending Reach of Checkpoint Blockade in Pancreatic Cancer
  • Case Report: RNA CAR T Cells
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement